Author(s):
Suyash Ingle, Abhilasha Waghmode, Gayatri Kasture, Manuja Ugade, Mehak Shaikh
Email(s):
suyashingle1806@gmail.com
DOI:
10.52711/2231-5691.2026.00013 
Address:
Suyash Ingle, Abhilasha Waghmode, Gayatri Kasture, Manuja Ugade, Mehak Shaikh
Dept of Pharmaceutical Quality Assurance, Gandhi Natha Rangji college of Pharmacy, Solapur, Maharashtra, India-413002.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2026
ABSTRACT:
ABSTRACT:
Guillain-Barré syndrome (GBS) is an extremely uncommon immune-mediated condition that primarily affects previously healthy people and is characterised by progressive muscle weakness and peripheral nerve system demyelination. It is severe enough to require hospitalization for treatment and typically manifests as ascending paralysis. GBS affects 1.1 to 1.8 out of every 100,000 people annually, and the frequency rises with age. Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN), Acute Motor and Sensory Axonal Neuropathy (AMSAN), and Miller Fisher Syndrome (MFS) are all included in the diverse clinical spectrum of GBS. Patients of all ages often experience the disease's hallmark, symmetrical limb weakness, which develops quickly and lasts for days to four weeks. Additionally, the majority of patients have sensory issues including tingling or a lackluster sensation. Acute flaccid paralysis is now most frequently caused by GBS in affluent nations. GBS is still a serious illness even with better diagnosis and care. Effective therapies include plasma exchange and intravenous immunoglobulin, although supportive care both during and after hospitalization is also highly important. In this article we review the current understanding of pathophysiology and clinical features of GBS and its variants.
Cite this article:
Suyash Ingle, Abhilasha Waghmode, Gayatri Kasture, Manuja Ugade, Mehak Shaikh. Guillain-Barré Syndrome: Pathogenesis, Clinical Features, Diagnostic Standards and Therapy. Asian Journal of Pharmaceutical Research. 2026; 16(1):97-0. doi: 10.52711/2231-5691.2026.00013
Cite(Electronic):
Suyash Ingle, Abhilasha Waghmode, Gayatri Kasture, Manuja Ugade, Mehak Shaikh. Guillain-Barré Syndrome: Pathogenesis, Clinical Features, Diagnostic Standards and Therapy. Asian Journal of Pharmaceutical Research. 2026; 16(1):97-0. doi: 10.52711/2231-5691.2026.00013 Available on: https://asianjpr.com/AbstractView.aspx?PID=2026-16-1-13
REFERENCE:
1. Guillain-Barré syndrome: clinical profile and management. GMS German Medical Science. 2015; 13.2.
2. Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain-Barre syndrome. The Journal of the Association of Physicians of India. 2013; 61(3):168-7
3. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain J Neurol 1995; 118(Pt 3):597-605. doi:10.1093/brain/118.3.597
4. Derksen A, Ritter C, Athar P, et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve 2014; 50(5):780-784. doi:10.1002/mus.24226
5. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy:beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol2013; 124(10):1928-1934. doi:10.1016/j.clinph.2013.03.025
6. Inoue N, Ichimura H, Goto S, Hashimoto Y, Ushio Y. MR imaging findings of spinal posterior column involvement in a case of Miller Fisher syndrome. AJNR Am J Neuroradiol 2004; 25(4):645-648.
7. Che Y, Qiu J, Jin T, et al. Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome. Sci Rep 2016; 6: 20963. doi:10.1038/srep20963
8. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010; 67(6):781-787.doi:10.1002/ana.21976
9. Burakgazi AZ, Höke A. Respiratory muscle weakness in peripheral neuropathies. J Peripher Nerv Syst 2010; 15(4):307-313.
10. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005; 116(1):8-14. doi:10.1542/peds.2004-1324
11. Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007; 2007(1): CD004761.doi:10.1002/14651858.CD004761.pub2
12. Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry 2005; 76(5):719-722.doi:10.1136/jnnp.2004.051136
13. Walteros DM, Soares J, Styczynski AR, et al. Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection. PLOS ONE 2019; 14(8):e0220049. doi:10.1371/journal.pone.0220049
14. Sepehrar M, Khorram H, Raja SK, Kothandapani S, Noroozpour Z, Sham MA, Prasad N, Sunny SP, Mohammed MD. Guillain-Barré syndrome: clinical profile and management. GMS German Medical Science. 2015; 13.
15. Omkar A. Devade, Rohan D. Londhe, Nikhil M. Meshram. Review on Spinal Muscular Atrophy. Research Journal of Pharmacology and Pharmacodynamics.2022; 14(4):246-2.
16. Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol.1990; 27(S1):S7http://dx.doi.org/10.1002/ana.410270704; PMid:2194431
17. S Sreeni, Nafiya Muhammed Zackariah, Lakshmi R. A Case Report: Morvan’s Syndrome. Research J. Pharm. and Tech. 2017; 10(4): 1174-1178
18. Orlikowski D, Prigent H, Sharshar T, Lofaso F, Raphael JC. Respiratory dysfunction Guillain-Barré Syndrome.Neurocrit Care. 2004; 1(4):415-22. http://dx.doi.org/10.1385/NCC:1:4:415.
19. Suman Sharma, Deepinder Singh, Ashima Katyal, Paramjeet S. Gill, Surender Jangra, Bhupender Bhardwaj, Usha Bhocal. Evaluation of outcome of disease in COVID-19 patients with Comorbidities: An experience from a Tertiary Care Center in North India. Research Journal of Pharmacy and Technology. 2024; 17(1):31-6